⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CABA News
Cabaletta Bio, Inc. Common Stock
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
globenewswire.com
CABA
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
globenewswire.com
CABA
Form 8-K
sec.gov
CABA
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
businesswire.com
CABA
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
BIIB
NVS
VTRS
UCB
BMY
ABBV
AZN
CABA
AUR
GSK
VERA
KYMR
NKTR
VRTX
ARWR
Form 8-K
sec.gov
CABA
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
CABA
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
prnewswire.com
GILD
INCY
BIIB
NVS
AMGN
JNJ
ABBV
BMY
AZN
MRK
PFE
TGTX
XNCR
CABA
IMUX
ZNTL
GLPG
CLNN
AUTL
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
globenewswire.com
CABA